R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.
Mast Cell Chymase/CMA1 (F6S4Q) Rabbit mAb #18992
Filter:
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | |
| Source/Isotype | Rabbit IgG |
Application Key:
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Immunohistochemistry (Paraffin) | 1:50 - 1:200 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
Mast Cell Chymase/CMA1 (F6S4Q) Rabbit mAb recognizes endogenous levels of total mast cell chymase/CMA1 protein.
Species Reactivity:
Human
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Dog
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Thr195 of human mast cell chymase/CMA1 protein.
Background
Mast cell chymase, also known as chymase 1 (CMA1), is one of the major proteases expressed and secreted by mast cells (1). CMA1 is found in cytoplasmic granules before it is released. It converts angiotensin I to angiotensin II and is the major enzyme responsible for doing so in the heart (2). CMA1 can promote pathogenesis of chronic obstructive pulmonary disease (COPD) by inducing TNF-α in lung macrophages (3). CMA1 activity is also implicated in fibrosis in various tissues (4). In COVID-19 patients, CMA1-positive mast cells are significantly elevated, and CMA1 levels are associated with disease severity (5,6). In gastric cancer, CMA1 has been proposed as a prognostic marker, with high expression associated with poor overall survival and with high levels of tumor-infiltrating lymphocytes (TILs) (7).
- Pejler, G. et al. (2010) Blood 115, 4981-90.
- Urata, H. et al. (1990) Circ Res 66, 883-90.
- Liu, G. et al. (2022) Eur Respir J 60, 2101431.
- Pejler, G. (2020) J Innate Immun 12, 357-372.
- Budnevsky, A.V. et al. (2022) Respir Res 23, 371.
- Wismans, L.V. et al. (2023) Histopathology 82, 407-419.
- Shi, S. et al. (2020) Autoimmunity 53, 210-217.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.